Alzheimer’s disease (AD) involves the complement cascade, with complement component 3 (C3) playing a key role. However, the relationship between C3 and amyloid beta (Aβ) in blood is limited.
Plasma C3 and Aβ oligomerization tendency (AβOt) were measured in 35 AD patients and 62 healthy controls. Correlations with cerebrospinal fluid (CSF) biomarkers, cognitive impairment, and amyloid positron emission tomography (PET) were analyzed. Differences between biomarkers were compared in groups classified by concordances of biomarkers.
Plasma C3 and AβOt were elevated in AD patients and in CSF or amyloid PET–positive groups. Weak positive correlation was found between C3 and AβOt, while both had strong negative correlations with CSF Aβ42 and cognitive performance. Abnormalities were observed for AβOt and CSF Aβ42 followed by C3 changes.
Increased plasma C3 in AD are associated with amyloid pathology, possibly reflecting a defense response for Aβ clearance. Further studies on Aβ-binding proteins will enhance understanding of Aβ mechanisms in blood.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Kyu Hwan Shim,
Danyeong Kim,
Min Ju Kang,
Jung‐Min Pyun,
Young Ho Park,
Young Chul Youn,
Kyung Won Park,
Kyoungho Suk,
Ho‐Won Lee,
Bárbara Fernandes Gomes,
Henrik Zetterberg,
Seong Soo A. An,
SangYun Kim,
for the Alzheimer’s Disease All Markers (ADAM) Research group | February 27, 2024

Wiley: Alzheimer’s & Dementia: Table of Contents